Since activity of CUGBP1 is controlled by GSK3β, correction of GSK3β in CDM1 or DM1 models restores CUGBP1 activity and improves muscle (myotonia, weakness, atrophy, myopathy) and CNS (anxiety) phenotypes. The gene discussed is CELF1; the disease is Myotonia.